Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Sandoz Tested Erelzi’s Suffix On Multiple Fronts

Feb 20 2017

• By Sue Sutter

Related Content

Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Jan 13 2017

How To Name A Biosimilar: Amgen Persisted With Amjevita Suffix Despite FDA Doubts

Feb 20 2017

FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say

Feb 16 2017

FDA Biosimilar Naming Policy Takes Middle-Of-The-Road Approach

Aug 27 2015

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi

Aug 31 2016

Related Companies

Novartis AG

Amgen, Inc.

Novartis AG

Additional Topics

United States Biosimilars Regulation Drug Review Profile BioPharmaceutical Dermatology Inflammation

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window